AstraZeneca’s relationship with the NHS is at the centre of our UK Marketing Company activities.
The NHS is the primary customer for AstraZeneca medicines in the UK and we engage with NHS staff on many levels on a daily basis.
We interact with healthcare professionals as part of our sales and marketing work, ensuring that clinicians have the best access to information about our medicines in order to make appropriate prescribing decisions.
At both national and local level, we work closely with NHS staff to help facilitate decision-making and budgetary planning. We’re committed to ensuring that AstraZeneca’s business is aligned with NHS priorities and supports delivery of excellent patient care.
Our UK Marketing Company takes a wholly customer-centric approach to our relationships with the NHS. This enables us to work more collaboratively through a better understanding of the needs of the healthcare professionals, commissioners and patients who use our medicines.
Joint Working with the NHS
Joint Working provides the formal foundation for creating, developing and implementing innovative healthcare solutions, which deliver better health outcomes for patients and the NHS. The Department of Health defines Joint Working as “situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation of patient-centred projects and share a commitment to successful delivery”.
The Department of Health and the Association of the British Pharmaceutical Industry (ABPI), of which AstraZeneca is a member, have worked together to produce valuable guidance to ensure that these partnerships are approached in the right way.
Through these partnerships, we were able to work with the NHS to pool skills, experience and resources to benefit patients.
By combining our resources and expertise, we can improve the lives of patients in line with best practice NICE and NHS guidelines, as well ensuring that more people can access the innovative medicines they need, build trust with our NHS stakeholders and help the NHS achieve its objectives, as well ensuring that more people can access the innovative medicines they need, and can also provide a commercial return to AstraZeneca when they need them.
AstraZeneca has a commitment to openness and transparency with regard to any donations, sponsorship or partnership funding it provides and, in line with the ABPI Code of Practice, will document and publicly disclose transfers of value made directly or indirectly to health professionals and healthcare organisations.